Chiyoda, CB&I reach deal with Golden Pass LNG for first train

Japan's Chiyoda and US-based CB&I have reached a deal with Golden Pass LNG, a joint venture owned by QatarEnergy and ExxonMobil, to complete the construction of the first liquefaction at the giant LNG export plant in Texas.

This story requires a subscription

Get 12 months of full digital access to LNG Prime for only $295 instead of $600.
This includes a single user license.
Check our FAQ for more info. For group subscriptions please contact us.

Most Popular

Spot LNG shipping rates slightly up this week

Spot charter rates for the global liquefied natural gas (LNG) carrier fleet rose slightly this week compared to the previous week.

Nigeria LNG seals long-term gas supply deals

LNG producer Nigeria LNG, a joint venture of NNPC, Shell, TotalEnergies, and Eni, has signed six long-term gas agreements to secure supplies for its Bonny Island plant, including the terminal's expansion.

Gastrade in talks to receive new LNG cargoes at Alexandroupolis FSRU

Greece's Gastrade is in talks with firms to receive the next spot LNG cargoes at the Alexandroupolis FSRU-based terminal since the shutdown in January this year.

More News Like This

NYK, partners take delivery of QatarEnergy LNG carrier

Japan’s NYK and its partners K Line, Malaysia’s MISC, and China’s CLNG have taken delivery of a 174,000-cbm LNG carrier built under the massive QatarEnergy shipbuilding program.

Another QatarEnergy LNG carrier named in China

Chinese shipbuilder Hudong-Zhonghua hosted a naming ceremony for another LNG carrier built under the massive QatarEnergy shipbuilding program.

Chiyoda scores contract for third Hibiki LNG tank

Japanese engineering firm Chiyoda has secured a contract from compatriot Saibu Gas to build the third liquefied natural gas (LNG) storage tank at the latter's Hibiki regasification terminal in Kitakyushu.

QatarEnergy LNG tanker wraps up trials in China

A 174,000-cbm LNG carrier built as part of the massive QatarEnergy shipbuilding program has completed its trials in China, according to Hudong-Zhonghua.